Compounds and compositions for the treatment of parasitic diseases

A compound of Formula I,

• or a pharmaceutical acceptable salt, tautomer or stereoisomer thereof, wherein
• n is 0, 1, 2 or 3;
• p is 0, 1, 2 or 3;
• L is selected from the group consisting of *—(CHR3)1-3—, *—CHR3N(R2)—, *—CHR3O—, *—CHR3S—, *—CHR3S(O)—, *—CHR3N(R2)CHR3—, *—C(O)—, *—C(O)N(R2)—, *—C(O)N(R2)CHR3—, *—N(R2)—, *—N(R2)CHR3—, *—N(R2)C(O)—, *—N(R2)C(O)N(R2)—, *—N(R2)S(O)2—, wherein
• * represents the point of attachment of L to the pyrazolo[1,5-a]pyridine fused ring depicted in Formula I;
• each R2 is independently selected from the group consisting of hydrogen, C1-6alkyl, haloC1-6alkyl, R—C0-4alkylene, and R—C0-4alkylene-C(O)—, wherein R is selected from the group consisting of hydroxyl, C1-4alkoxy, amino, C1-4alkylamino, C3-6cycloalkyl, C4-6heterocycloalkyl, and C5-6heteroaryl, wherein the C3-6cycloalkyl, C4-6heterocycloalkyl, and C5-6heteroaryl of R are each unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of halo, amino, hydroxyl, C1-4alkyl, C1-4alkoxy, oxo, and C5-6heteroaryl;
• and
• each R3 is independently selected from the group consisting of hydrogen and C1-4alkyl;
• Ring A is selected from the group consisting of C6-10aryl and C3-10heteroaryl;
• Ring C is selected from the group consisting of C6-10aryl, C5-10heteroaryl, C5-7cycloalkyl, C5-7heterocycloalkyl, and fused bicyclyl comprising a C5-6heterocycloalkyl fused to a phenyl;
• each R1 is independently selected from the group consisting of halo, cyano, amino, C1-4alkyl, C1-4alkoxyl, halo-C1-4alkyl, —C(O)NR7R8, —NHC(O)R11, phenyl, and C5-6heteroaryl;
• wherein
• the phenyl and C5-6heteroaryl of R1 are each unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of C1-4alkyl, amino, halo, and C1-4alkylamino;
• R7 and R8 are each independently selected from hydrogen, C1-4alkyl and haloC1-4alkyl;
• R11 is C1-6alkyl, unsubstituted or substituted with 1-2 substituents independently selected from the group consisting of amino, C3-6cycloalkyl and C4-6heterocycloalkyl;
• R17 is selected from the group consisting of cyano, halo, C1-4alkyl, halo-C1-4alkyl, oxo, C3-6cycloalkyl, and —SO2—C1-4alkyl.